

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1-15. (Canceled)
16. (New) An isolated antibody, or fragment thereof, that
 - (a) binds to a peptide transporter and
 - (b) inhibits peptide uptake into a cell expressing the peptide transporter, wherein the antibody is a monoclonal or genetically engineered recombinant antibody, or antigen-binding fragment thereof.
17. (New) The antibody or fragment thereof of claim 16, wherein the peptide transporter is a proton motive force (PMF) dependent transporter.
18. (New) The antibody or fragment thereof of claim 16, wherein the peptide transporter is PepT1.
19. (New) The antibody or fragment thereof of claim 16, wherein the peptide transporter is PepT2.
20. (New) The antibody of claim 16, wherein the antibody is monoclonal.
21. (New) The antibody or fragment thereof of claim 16, wherein the antibody or fragment thereof is recombinant.

22. (New) The antibody of claim 16, wherein the antibody is humanized or chimeric.
23. (New) The antibody or fragment thereof of claim 16, wherein the antibody is bispecific.
24. (New) A diabody that binds to a peptide transporter and inhibits peptide uptake into a cell expressing the peptide transporter.
25. (New) A composition comprising the antibody or fragment thereof of claim 16 and a pharmaceutically acceptable carrier, wherein the antibody or fragment thereof inhibits the growth of a cell.
26. (New) The composition of claim 25, wherein the cell is a cancer cell.
27. (New) The composition of claim 25, wherein the cell is a pancreatic cancer cell.
28. (New) A method for inhibiting peptide transporter activity, the method comprising contacting the antibody or fragment thereof of claim 16 with a cell expressing the peptide transporter.
29. (New) The method of claim 28, wherein the peptide transporter is a PMF dependent transporter.
30. (New) The method of claim 28, wherein the peptide transporter protein is PepT1.
31. (New) The method of claim 28, wherein the peptide transporter protein is PepT2.
32. (New) The method of claim 28, wherein the antibody is monoclonal.

- 33. (New) The method of claim 28, wherein the cell is *in vivo*.
- 34. (New) The method of claim 28, wherein the antibody is human or humanized.
- 35. (New) A method for suppressing cell growth, the method comprising contacting the antibody or fragment thereof of claim 16 with a cell expressing the peptide transporter.
- 36. (New) The method of claim 35, wherein the antibody is monoclonal.
- 37. (New) The method of claim 35, wherein the cell is *in vivo*.
- 38. (New) The method of claim 35, wherein the antibody is human or humanized.
- 39. (New) The method of claim 35, wherein the peptide transporter is a PMF-dependent transporter.
- 40. (New) The method of claim 35, wherein the peptide transporter is PepT1.
- 41. (New) The method of claim 35, wherein the peptide transporter is PepT2.
- 42. (New) The method of claim 35, wherein the cell is a cancer cell.
- 43. (New) The method of claim 35, wherein the cell is a pancreatic cancer cell.